Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+4.29%
-1.32%
-14.99%
+22.09%
-1.56%
HUMA
Humacyte
$1.64
Login to see Humacyte (HUMA) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Upgraded on attractively valued
Chart
$1.5 (+9.33%)
$2.39 (-31.38%)
$2.24 (-26.79%)
$5.48 (-70.07%)
HUMA has Extreme Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
Price under $5
High volatilty
HUMA overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Reported a weak earnings
Has a weak balance sheet
Below analyst estimate
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Future
Future
HUMA Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
HUMA Street view is bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayHUMA Earnings
The TTM reflects 12-month period, providing review of HUMA financial performance.
The company financial health is gradually deteriorating, indicating rising risks and weakening fundamentals
Financial Score
What is HUMA current stock price?
What are HUMA stock strengths?
What risks are associated with HUMA stock?
When is HUMA next earnings report?
What is HUMA market cap and volume?
What is HUMA's current Stock IQ?
Should I buy HUMA stock right now?
Is HUMA a Strong Buy right now?
What does a 'Strong Buy' rating mean for HUMA?
What does a 'Strong Sell' rating mean for HUMA?
What factors influence HUMA's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+4.29%
-1.32%
-14.99%
+22.09%
-1.56%
HUMA
Humacyte
Current Price
$1.64
Stock Insights
Strengths
Upgraded on attractively valued
Login to unlock Humacyte (HUMA) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$1.5 (+9.33%)
$2.39 (-31.38%)
$2.24 (-26.79%)
$5.48 (-70.07%)
HUMA Analysts Opinion
HUMA Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Reported a weak earnings
Has a weak balance sheet
Below analyst estimate
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Future
Future
HUMA Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
HUMA Street view is bullish and have positive views on the near-term outlook
HUMA has Extreme Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
Price under $5
High volatilty
Average key support and resistance price levels.
Login to displayHUMA Earnings
The TTM data reflects the most recent 12-month period, providing overview of HUMA financial performance.
HUMA Financial Health
The company financial health is gradually deteriorating, indicating rising risks and weakening fundamentals
Financial Score
HUMA Latest Analysis
Humacyte: Shares Tank On Fundraising News - What You Need To Know.
Tue Oct 7, 2025
Humacyte shares sink as it announces pricing of $60M direct offering.
Tue Oct 7, 2025
D. Boral Capital Maintains Humacyte (HUMA) Buy Recommendation. Fintel reports that on October 6 2025 D. Boral Capital maintained coverage of Humacyte (NasdaqGS:HUMA) with a Buy recommendation. Analyst Price Forecast Suggests 281.98% Upside
Tue Oct 7, 2025
Humacyte rises after positive data from humanitarian study of Symvess.
Mon Oct 6, 2025
D. Boral Capital Maintains Humacyte (HUMA) Buy Recommendation. Fintel reports that on September 30 2025 D. Boral Capital maintained coverage of Humacyte (NasdaqGS:HUMA) with a Buy recommendation. Analyst Price Forecast Suggests 259.65% Upside
Tue Sep 30, 2025
Humacyte (HUMA) Price Target Increased by 51.64% to 9.44. The average one-year price target for Humacyte (NasdaqGS:HUMA) has been revised to $9.44 / share. This is an increase of 51.64% from the prior estimate of $6.22 dated September 10 2025. The price target is an average of many targets provided by analysts. The
Tue Sep 30, 2025
Humacyte Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note. Humacyte Inc. (HUMA) concluded the recent trading session at $1.77 signifying a -4.84% move from its prior days close.
Mon Sep 22, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
HUMA Stock trends
HUMA Stock performance
HUMA Stock analysis
HUMA investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings
Leaders